Active Ingredient(s): Tazemetostat Hydrobromide
FDA Approved: * January 23, 2020
Pharm Company: * EPIZYME INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tazverik Overview

Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).[1] The most common side eff...

Read more Tazverik Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tazemetostat

Recent Tazverik Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tazemetostat Hydrobromide
  • Tablet: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tazverik: (1 result)

Sorted by National Drug Code
  • 72607-100 Tazverik 200 mg Oral Tablet, Film Coated by Epizyme, Inc.

Other drugs which contain Tazemetostat Hydrobromide or a similar ingredient: (1 result)